Partnering & Collaborations
Built on Collaboration
We work closely with academic institutions, biotech innovators, and manufacturing partners to accelerate the translation of breakthrough science into clinical impact. Repairon Immuno is part of a broader regenerative medicine ecosystem leveraging shared expertise in stem cell biology, GMP manufacturing, and clinical development.
Current Partnerships
Repairon
The medical need for regenerative therapies in advanced heart failure patients with high mortality and low quality of life is enormous. Existing therapies delay disease progression, but cannot repair the failing heart. The penultimate therapy, heart transplantation, is and will remain a therapeutic option only for very few patients. Repairon’s mission is the development, the manufacturing and the commercialization of induced pluripotent stem cell (iPSC) based tissues for organ repair. Our lead product are contractile heart tissue patches – Engineered Human Myocardium (EHM) – for the treatment of patients with advanced heart failure. Implantation of contractile EHM-patches is a unique option to remuscularize and heal the failing heart. Our vision is that in the future, EHM-based therapies will make heart transplantation and mechanical circulatory support devices obsolete.
BAYCELLator
Chimeric antigen receptor-based immunocellular therapy has emerged as a groundbreaking advancement in the field of cancer treatment. Despite delivering remarkable clinical outcomes, therapies that rely on a patient's own cells face limitations due to extended manufacturing times, high costs, and the challenge of procuring an adequate number of cells from individuals who have undergone multiple rounds of prior chemotherapy. Off-the-shelf or allogeneic CAR cell products offer promising alternatives to address these associated challenges. Induced pluripotent stem (iPS) cells present a highly favorable cell source for cellular therapies, thanks to their unlimited capacity for proliferation, ease of genetic modification, and their ability to differentiate into immune cells, including T and NK cells. In the collaborative Baycellator project between TUM and Repairon Immuno, our shared objective is the development, production, and commercialization of iPS cell-derived immune cell products for innovative therapeutic solutions.
